

Armando Abergel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1187369/armando-abergel-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

1,401
citations

13
h-index

25
g-index

25
ext. papers

1,629
ext. citations

8.7
avg, IF

3.59
L-index

#	Paper	IF	Citations
23	Microsporidiosis after liver transplantation: A French nationwide retrospective study. <i>Transplant Infectious Disease</i> , 2021 , 23, e13665	2.7	1
22	Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity. <i>Metabolites</i> , 2021 , 11,	5.6	2
21	Letter: is the AHHS score really useful in clinically severe alcoholic hepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1160-1161	6.1	
20	Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. <i>Liver International</i> , 2020 , 40, 1853-1859	7.9	7
19	Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?. <i>Nutrients</i> , 2020 , 12,	6.7	25
18	Extrahepatic portal vein obstruction (EHPVO) in cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 497-502	2.4	0
17	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. <i>Liver International</i> , 2020 , 40, 2385-2393	7.9	3
16	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. <i>Journal of Hepatology</i> , 2019 , 70, 1297-1300	13.4	2
15	Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz076	1	39
14	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 45-51	18.8	38
13	12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. <i>Hepatology</i> , 2018 , 68, 1277-1287	11.2	7
12	Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 916-924	4	18
11	Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts ¹ H-NMR Spectroscopy. <i>Metabolites</i> , 2017 , 7,	5.6	15
10	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. <i>Hepatology</i> , 2016 , 64, 1049-56	11.2	91
9	Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 459-64	25.5	82
8	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2599-607	59.2	758
7	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , 2014 , 147, 132-142.e4	13.3	207

6	Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma. <i>Anticancer Research</i> , 2014 , 34, 7247-53	2.3	5
5	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011 , 11, 496-503	4.5	13
4	Growth arrest and decrease of alpha-SMA and type I collagen expression by palmitic acid in the rat hepatic stellate cell line PAV-1. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 986-95	4	24
3	Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 1219-27	2.2	24
2	Treatment of the rat hepatic stellate cell line, PAV-1, by retinol and palmitic acid leads to a convenient model to study retinoids metabolism. <i>Biology of the Cell</i> , 2002 , 94, 401-8	3.5	10
1	PAV-1, a new rat hepatic stellate cell line converts retinol into retinoic acid, a process altered by ethanol. <i>International Journal of Biochemistry and Cell Biology</i> , 2002 , 34, 1017-29	5.6	29